CIK 0000914475 · Large accelerated filer
NEUROCRINE BIOSCIENCES INC
Sign in to watch- Ticker
- NBIX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 330525145
- Phone
- (858) 617-7600
- Business address
- 6027 EDGEWOOD BEND COURT, SAN DIEGO, CA, 92130
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $3,162,347
- in 4 filings, $3.2M under 10b5-1 plans
Net −$3,162,347. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-02-28 | Delaet Ingrid Chief Regulatory Officer | Option exercise 10b5-1 | +2,500 | $79.02 | $198K | 10,007 |
| 2024-02-28 | Delaet Ingrid Chief Regulatory Officer | Sale 10b5-1 | −2,500 | $134.62 | $337K | 7,507 |
| 2024-02-28 | Delaet Ingrid Chief Regulatory Officer | Option exercise 10b5-1 | +1,544 | $79.02 | $122K | 9,051 |
| 2024-02-28 | Delaet Ingrid Chief Regulatory Officer | Sale 10b5-1 | −1,544 | $136.00 | $210K | 7,507 |
| 2024-02-28 | Delaet Ingrid Chief Regulatory Officer | Option exercise · Non-Qualified Stock Option 10b5-1 | −2,500 | $79.02 | $198K | 9,761 |
| 2024-02-28 | Delaet Ingrid Chief Regulatory Officer | Option exercise · Non-Qualified Stock Option 10b5-1 | −2,500 | $79.02 | $198K | 7,261 |
| 2024-02-28 | Delaet Ingrid Chief Regulatory Officer | Option exercise · Non-Qualified Stock Option 10b5-1 | −1,544 | $79.02 | $122K | 5,717 |
| 2024-02-28 | BENEVICH ERIC Chief Commercial Officer | Option exercise 10b5-1 | +53,143 | $43.24 | $2.3M | 93,759 |
| 2024-02-28 | BENEVICH ERIC Chief Commercial Officer | Sale 10b5-1 | −53,143 | $134.69 | $7.2M | 40,616 |
| 2024-02-28 | BENEVICH ERIC Chief Commercial Officer | Option exercise 10b5-1 | +21,857 | $79.02 | $1.7M | 62,473 |
| 2024-02-28 | BENEVICH ERIC Chief Commercial Officer | Sale 10b5-1 | −21,857 | $134.69 | $2.9M | 40,616 |
| 2024-02-28 | BENEVICH ERIC Chief Commercial Officer | Option exercise · Non-Qualified Stock Option 10b5-1 | −53,143 | $43.24 | $2.3M | 0 |
| 2024-02-28 | BENEVICH ERIC Chief Commercial Officer | Option exercise · Non-Qualified Stock Option 10b5-1 | −21,857 | $79.02 | $1.7M | 39,360 |
| 2024-02-27 | Norwalk Leslie V Director | Option exercise 10b5-1 | +8,000 | $84.95 | $680K | 8,000 |
| 2024-02-27 | Norwalk Leslie V Director | Sale 10b5-1 | −8,000 | $135.67 | $1.1M | 0 |
| 2024-02-27 | Norwalk Leslie V Director | Option exercise · Non-Qualified Stock Option 10b5-1 | −8,000 | $84.95 | $680K | 1,724 |
| 2024-02-20 | POPS RICHARD F Director | Option exercise 10b5-1 | +15,000 | $12.98 | $195K | 44,512 |
| 2024-02-20 | POPS RICHARD F Director | Sale 10b5-1 | −15,000 | $132.47 | $2.0M | 29,512 |
| 2024-02-20 | POPS RICHARD F Director | Option exercise · Non-Qualified Stock Option 10b5-1 | −15,000 | $12.98 | $195K | 0 |
| 2024-02-13 | ROBERTS EIRY Chief Medical Officer | Sale 10b5-1 | −1,114 | $132.96 | $148K | 23,716 |
Page 36 of 37 · 740 trades